Lupin signs patent licence pact with Takeda for novel gastrointestinal drug in Indian market

Under the terms of this agreement, Takeda has granted Lupin non-exclusive patent licensing rights to commercialise Vonoprazan in India.

Lupin signs patent licence pact with Takeda for novel gastrointestinal drug in Indian market
Lupin President India Region Formulations Rajeev Sibal said Vonoprazan is a novel treatment option for acid peptic disorders.

Home-grown pharma major Lupin Ltd on Wednesday said it has entered into a non-exclusive patent licence agreement with Takeda Pharmaceutical Company Ltd to commercialise Vonoprazan tablets, a novel gastrointestinal drug, in the Indian market.

Under the terms of this agreement, Takeda has granted Lupin non-exclusive patent licensing rights to commercialise Vonoprazan in India, the company said in a regulatory filing.

The drug will be marketed under the brand name Lupin's Lupivon and will be available in two strengths -- 10 mg and 20 mg, it added.

Lupin President India Region Formulations Rajeev Sibal said Vonoprazan is a novel treatment option for acid peptic disorders.

The pact with Takeda is "a further step in strengthening our gastroenterology portfolio and is in line with our commitment to introduce innovative medicines to address unmet needs of our patients," he added.

In India, Vonoprazan is approved by the DCGI (Drugs Controller General of India) for treating reflux esophagitis, gastric ulcers, duodenal ulcers, and as part of Helicobacter pylori eradication treatment, Lupin said in the filing.

Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.

RECOMMENDED STORIES

https://www.zeebiz.com/personal-finance/photo-gallery-power-of-compounding-how-soon-will-monthly-sip-of-rs-11000-reach-rs-8-crore-corpus-target-retirement-financial-planning-with-sip-calculator-334296

Power of Compounding: How soon will monthly SIP of Rs 11,000 reach Rs 8 crore corpus target?

https://www.zeebiz.com/personal-finance/photo-gallery-rs-3500-monthly-sip-for-35-years-vs-rs-35000-monthly-sip-for-16-years-which-can-give-you-higher-corpus-in-long-term-compound-interest-benefits-mutual-fund-return-calculator-retirement-planning-334249

Rs 3,500 Monthly SIP for 35 years vs Rs 35,000 Monthly SIP for 16 Years: Which can give you higher corpus in long term? See calculations

https://www.zeebiz.com/market-news/news-short-term-investment-ideas-stocks-to-buy-for-15-days-axis-direct-recommends-fortis-healthcare-aegis-logistics-check-targets-334316

Looking for short term investment ideas? Analysts suggest buying these 2 stocks for potential gain; check targets

https://www.zeebiz.com/personal-finance/photo-gallery-ppf-interest-rate-maturity-retirement-corpus-planning-calculator-how-to-get-inr-rs-72000-month-tax-free-income-from-public-provident-fund-calculations-80c-tax-benefits-333983

PPF Calculations: How to get Rs 72,000 a month tax-free income from Public Provident Fund?

https://www.zeebiz.com/personal-finance/news-rs-1111-monthly-sip-for-40-yrs-11111-for-20-yrs-or-22222-for-10-years-which-works-best-at-same-expected-return-334395

Small SIP, Big Impact: Rs 1,111 monthly SIP for 40 years, Rs 11,111 for 20 years or Rs 22,222 for 10 years, which do you think works best?

Written By: PTI
Updated: Wed, Sep 18, 2024
02:56 PM IST
New Delhi, PTI
RELATED NEWS
Lupin gets 6 observations from USFDA for Pithampur plant Lupin gets 6 observations from USFDA for Pithampur plant
Sunsure Energy to supply 21 MW solar power to Lupin Sunsure Energy to supply 21 MW solar power to Lupin
Global brokerages bullish on Lupin a day after its con call; check out target Global brokerages bullish on Lupin a day after its con call; check out target
Lupin Q1 FY25 Results Preview: Net profit likely to grow by one-third, margin may improve by 200 bps; here is what else you can expect Lupin Q1 FY25 Results Preview: Net profit likely to grow by one-third, margin may improve by 200 bps; here is what else you can expect

By accepting cookies, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.

x